logo
Sign in

INOVIO PHARMACEUTICALS, INC.

Plymouth Meeting, PA · Biotech · Public

DNA plasmid-based immunotherapies and vaccines

Claim this profile

Follows are private to you and power your alerts

Updated · inovio.com

Sector
Biotech
Headquarters
Plymouth Meeting, PA
Latest Form D
$4M, Jan 2020
Total capital
$31.2M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$19.2M
2 Form D · last Jan 2020
81 months since last filing
Federal contracts
$12M
2 awards · Defense
Rank in Biotech#56 of 4373
Granted patents
23
17 pending · first 2024
Rank in peer group#23 of 1449

Capital timeline

20112013201520172019FEDERAL ↑EQUITY ↓Cumulative $31.2M$1.3M$10.7M1st Form D$15.2M2nd Form D$4M
20112013201520172019FEDERAL ↑EQUITY ↓Cumulative $31.2M$1.3M$10.7M1st Form D$15.2M

Latest events

  • Federal contractDefense · Cellectra 2000 Array$10.7M
  • Private capital raisedForm D · SEC · 2nd filing$4M
  • Private capital raisedForm D · SEC · 1st filing$15.2M
  • Federal contractDefense · SBIR Phase I Army 2010.3 Log # 11343003$1.3M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

102months

from INOVIO PHARMACEUTICALS, INC.’s first federal award to its first private round.

First federal award · Feb 2011
Defense · $1.3M
First Form D · Aug 2019
$15.2M · 1st Form D
Awards before first raise
1 award

An association in public records, not a cause or a prediction.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#23 · top 2%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Angel X. CabreraDirectorNamed in SEC Form D filings
  • Ann C. MillerDirectorNamed in SEC Form D filings
  • David B. WeinerDirectorNamed in SEC Form D filings
  • Jacqueline S. SheaExecutive OfficerNamed in SEC Form D filings
  • Jay X. ShepardDirectorNamed in SEC Form D filings
  • J. Jospeh KimExecutive Officer, DirectorNamed in SEC Form D filings
Show all 12 people
  • Laurent S. HumeauExecutive OfficerNamed in SEC Form D filings
  • Lota S. ZothDirectorNamed in SEC Form D filings
  • Morton X. CollinsDirectorNamed in SEC Form D filings
  • Peter Jospeh KiesExecutive OfficerNamed in SEC Form D filings
  • Simon X. BenitoDirectorNamed in SEC Form D filings
  • Wendy L. YarnoDirectorNamed in SEC Form D filings

What it has protected

USPTO · 23 granted of 40
Show all 40 patent records

Related companies, and why

  • ENALARE THERAPEUTICS INCSimilar federal contract value in Biotech · $13M in contracts
  • INIMMUNE CORPSimilar federal contract value in Biotech · $12.8M in contracts
  • ZATA PHARMACEUTICALS, INC.Similar federal contract value in Biotech · $12.6M in contracts
  • Twist BioscienceSimilar federal contract value in Biotech · $12M in contracts
  • Codagenix Inc.Similar federal contract value in Biotech · $11.2M in contracts
  • Ceramedix Holding, LLCSimilar federal contract value in Biotech · $10.2M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .